ReviewCancers2026
Immunotherapy in Locally Advanced Cervical Carcinoma: A Narrative Review.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune remodeling during cervical cancer chemoradiotherapy: temporal biomarkers and the timing of checkpoint blockade.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of locally advanced cervical cancer is based on concomitant cisplatin-based chemoradiotherapy followed by brachytherapy. The quality of this treatment is essential to optimize results. In particular, intensity-modulated radiotherapy followed by image-guided brachytherapy achieves 90% local control regardless of the stage of the disease. More recently, several randomized trials have changed the management of these tumors: The INTERLACE trial evaluated the benefits of neoadjuvant chemotherapy with carboplatin and paclitaxel and demonstrated a survival benefit for this approach. This trial has been the subject of considerable criticism. The KEYNOTE A.18 trial evaluated the addition of pembrolizumab to standard treatment: an improvement in overall survival was demonstrated for patients with stage III-IV disease (FIGO 2014 classification). The CALLA trial, which evaluated the addition of durvalumab, was negative. This review summarizes the biological rationale for this immunotherapy, its results, and the quality criteria for chemoradiotherapy. It describes the various trials in detail, puts their results into context, and discusses the relevance of this new treatment based on the patients' baseline characteristics. Based on this critical analysis, patients with stage III-IVA cervical cancer (FIGO 2014 classification) should receive, in addition to standard chemoradiotherapy, concomitant treatment with pembrolizumab followed by two years of maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.